Celera Corporation
Lung cancer markers and uses thereof
Methods and compositions are provided for assessing (e.g., diagnosing), treating, and preventing diseases, especially cancer, and particular lung cancer, using lung cancer markers (LCM). Individual LCM and panels comprising multiple LCM are provided for these and other uses. Methods and compositions are also provided for determining or predicting the effectiveness of a treatment or for selecting a treatment using LCM. Methods and compositions are further provided for modulating cell function using LCM. Also provided are compositions that modulate LCM (e.g., antagonists or agonists), such as antibodies, proteins, small molecule compounds, and nucleic acid agents (e.g., RNAi and antisense agents), as well as pharmaceutical compositions thereof. Further provided are methods of screening for agents that modulate LCM, and agents identified by these screening methods.
Celera Corporation
A C C G G C A G G G C G C C
A61P C12Q C12Q G01N G01N C12Q A61P G01N G01N G01N C12Q G01N C12Q C12Q
inventional additional additional inventional additional inventional inventional additional inventional inventional additional additional additional additional
Steve Marcia Mehdi Charles
Ruben Lewis Mesri Birse